Stephan Schwers

1.6k total citations
30 papers, 1.2k citations indexed

About

Stephan Schwers is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Stephan Schwers has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 8 papers in Genetics and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Stephan Schwers's work include Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Stephan Schwers is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Stephan Schwers collaborates with scholars based in Germany, United States and Netherlands. Stephan Schwers's co-authors include Klaus Rajewsky, Eiichiro Sonoda, Jan Stampfuss, Wolfgang Mueck, Raul M. Torres, David Nemazee, Roberta Pelanda, Yael Pewzner‐Jung, Shinsuke Taki and Steffen Jung and has published in prestigious journals such as Nature, Blood and Immunity.

In The Last Decade

Stephan Schwers

29 papers receiving 1.2k citations

Peers

Countries citing papers authored by Stephan Schwers

Since Specialization

Citations

This map shows the geographic impact of Stephan Schwers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Schwers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Schwers more than expected).

Fields of papers citing papers by Stephan Schwers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Schwers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Schwers. The network helps show where Stephan Schwers may publish in the future.

Co-authorship network of co-authors of Stephan Schwers

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Schwers. A scholar is included among the top collaborators of Stephan Schwers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Schwers. Stephan Schwers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers 2024 ·Clinical and Translational Science ·(unknown), (unknown), (unknown), Huijun Chen, (unknown), Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Z. Yu	7
2	The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence 2023 ·Journal of Thrombosis and Thrombolysis ·Sonja Schiffer, Stephan Schwers, Stefan Heitmeier	4
3	Predictive value for increased activated factor XI activity in acute venous thromboembolism 2023 ·Journal of Thrombosis and Haemostasis ·Magdolna Nagy, (unknown), Mayken Visser, Thomas Koeck, Vincent ten Cate, Arina J. ten Cate‐Hoek, Stephan Schwers, Stefan Heitmeier, Hugo Ten Cate, Philipp S. Wild, Henri M.H. Spronk	10
4	Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study 2022 ·British Journal of Clinical Pharmacology ·Dagmar Kubitza, (unknown), (unknown), (unknown), Stephan Schwers, Friederike Kanefendt	43
5	Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis 2022 ·Scientific Reports ·(unknown), Vincent ten Cate, Andreas Schulz, Jürgen H. Prochaska, Steffen Rapp, Thomas Koeck, Marina Panova‐Noeva, Stefan Heitmeier, Stephan Schwers, Kirsten Leineweber, Hans‐Jürgen Seyfarth, Christian Opitz, Henri M.H. Spronk, Christine Espinola–Klein, Karl J. Lackner, Thomas Münzel, Miguel A. Andrade‐Navarro, Stavros Konstantinides, Hugo Ten Cate, Philipp S. Wild	26
6	First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men 2022 ·Journal of Thrombosis and Haemostasis ·Bettina Nowotny, Dirk Thomas, Stephan Schwers, (unknown), (unknown), Ashraf Yassen, (unknown)	19
7	Clinical use of thrombin generation assays 2021 ·Journal of Thrombosis and Haemostasis ·Nikolaus B. Binder, François Depasse, (unknown), (unknown), Stephan Schwers, Matthias Germer, (unknown), Peter L. Turecek	69
8	First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa 2021 ·Journal of Thrombosis and Haemostasis ·Dirk Thomas, Friederike Kanefendt, Stephan Schwers, Sigrun Unger, Ashraf Yassen, (unknown)	59
9	BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics 2019 ·Research and Practice in Thrombosis and Haemostasis ·Dirk Thomas, Kirstin Thelen, Stefanie Kraff, Stephan Schwers, Sonja Schiffer, Sigrun Unger, Ashraf Yassen, (unknown)	58
10	Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study 2017 ·Journal of Thrombosis and Haemostasis ·Reinhold Kreutz, Pontus B. Persson, Dagmar Kubitza, Karin Thelen, Stefan Heitmeier, Stephan Schwers, Michael Becka, Melanie Hemmrich	38
11	Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum 2014 ·European Respiratory Journal ·Henrik Watz, Johannes Nagelschmitz, Frauke Pedersen, Felix C. Ringshausen, Anne Kirsten, H Magnussen, Klaus F. Rabe, Tobias Welte, Jessica Rademacher, Christine Rentzsch, Christian Schumann, (unknown), (unknown), Anja Schäfer, Stephan Schwers	2
12	The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations 2014 ·European Respiratory Journal ·Johannes Nagelschmitz, Michael Becka, (unknown), Stephan Schwers, Georg Wensing	2
13	The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases 2014 ·European Respiratory Journal ·Johannes Nagelschmitz, (unknown), Stephan Schwers, Franz von Nussbaum, (unknown), Martina Delbeck, Klemens Lustig, Tiemo J. Bandel, Henrik Watz	5
14	The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects 2014 ·European Respiratory Journal ·Johannes Nagelschmitz, Michael Becka, (unknown), Stephan Schwers, Franz von Nussbaum, (unknown), Georg Wensing	2
15	Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects 2013 ·Clinical Pharmacology in Drug Development ·Dagmar Kubitza, Michael Becka, Stephan Schwers, Barbara Voith	25
16	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring 2013 ·Thrombosis Journal ·Wolfgang Mueck, Stephan Schwers, Jan Stampfuss	129
17	Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin 2012 ·Thrombosis and Haemostasis ·Gabriele Rohde, Gertrud Stratmann, Christian W. Hesse, (unknown), Stephan Schwers, Elisabeth Perzborn, Edelgard Lindhoff‐Last, Helen Mani	82
18	Secondary V(D)J recombination in B-1 cells 1999 ·Nature ·F. Xiao‐Feng Qin, Stephan Schwers, Wong Yu, F. Nina Papavasiliou, Heikyung Suh, André Nussenzweig, Klaus Rajewsky, Michel C. Nussenzweig	62
19	B Cell Development under the Condition of Allelic Inclusion 1997 ·Immunity ·Eiichiro Sonoda, Yael Pewzner‐Jung, Stephan Schwers, Shinsuke Taki, Steffen Jung, Dan Eilat, Klaus Rajewsky	202
20	Receptor Editing in a Transgenic Mouse Model: Site, Efficiency, and Role in B Cell Tolerance and Antibody Diversification 1997 ·Immunity ·Roberta Pelanda, Stephan Schwers, Eiichiro Sonoda, Raul M. Torres, David Nemazee, Klaus Rajewsky	235

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact